Company Overview and News
New Zealand shares fell for a second day with Meridian Energy lower as the power company confronts dry conditions, and exporters Comvita and Fisher & Paykel Healthcare faced a stronger kiwi dollar.
RHCGF SPKKY EBOSY NZTCY SPK NZTCF RYM EBO SKT GNE AOTUF EBOSF SYKWF PPSHY RYHTY VTHPF SKKTY GNE MEZ GEL EBO
New Zealand shares fell for a seventh day. Rising US bond yields kept a lid on equity markets across Asia, weighing on growth-orientated stocks such as A2 Milk Co and Pushpay Holdings.
AIR FCREY ZNRGF NZTCF RYM ACKDF ANZFY AUKNY AIZ SKT ZNZ SYKWF PPSHY SKKTY SML AIA FBU RHCGF SPKKY NZTCY SPK ZEL FRCEF AIA FBU ANZLY RYHTY ANZFF MEZ
New Zealand shares fell for a sixth session as rising US bond yields dented investors' appetite for stocks. Synlait Milk led the market lower, dropping to a five-month low.
C6L PYIYY AIR NZTCF SINGY ACKDF ANZFY AUKNY AIZ GNE PPSHY GEL SML AIA SPKKY NZTCY SPK AIA ANZLY ANZFF GNE GTK MEZ PFI SINGF
New Zealand shares fell for a fourth day as A2 Milk Co remains out of favour after recent selling by its chief executive and a director. Genesis Energy and Auckland International Airport also declined after shedding rights to dividend payments.
CEN AIA FBU RHCGF FCREY CMO RYM ACKDF FRCEF AUKNY COENY KWIPF COENF GNE AIA PPSHY FBU RYHTY CEN GNE MEZ GEL
New Zealand shares slipped as the weakest business confidence in nine years and fears over future profitability weighed on stocks linked to the local economic cycle.
AIA FBU RHCGF AIR FCREY SPKKY NZTCY SPK NZTCF RYM ACKDF FRCEF ANZFY AUKNY AIZ SKT SYKWF AIA PPSHY FBU ANZLY RYHTY SKKTY ANZFF
New Zealand shares rose as investors shrugged off a slightly gloomier outlook for Synlait Milk and joined a global rally as the latest bout in the US-China trade war wasn't as harsh as feared.
KTHDY WBC SPKKY NZTCY SPK NZTCF WEBNF WBK KMD WBC PPSHY THL MS KMD SML
New Zealand shares joined the global rally in equity markets as the prospect of improving trade relations between the US and China lifted investor confidence. Pushpay Holdings led the market higher after getting a broker upgrade.
AIA FBU AIR FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF ANZFY AUKNY AIZ FTRRF AIA PPSHY FBU THL ANZLY ANZFF
New Zealand shares dropped as investors picked a weaker outlook for Air New Zealand and Ebos. Fisher & Paykel Healthcare Corp and Auckland International Airport gained on expectations for continuing strong earnings growth.
TME AIA TRMEF WBC AIR SPKKY NZTCY SPK NZTCF WEBNF WBK ACKDF ANZFY AUKNY AIZ AIA WBC PPSHY ANZLY TME ANZFF TDMEY
New Zealand shares hit another record amidst a slew of earnings, with Trade Me Group and A2 Milk Co gaining on their annual accounts while Fletcher Building dropped.
TME TRMEF FBU WBC FCREY SPKKY NZTCY SPK NZTCF WEBNF WBK FRCEF WBC PPSHY FBU TME TDMEY MEZ
New Zealand shares rose as investors took stock in a brief lull to the domestic corporate earnings season, with Skellerup Holdings extending yesterday's gain to break a new record.
CEN AIR NZTCF RYM ACKDF ANZFY AUKNY AIZ COENF GNE AOTUF SKC PPSHY CEN SNZ SKL GEL AIA RHCGF SPKKY NZTCY SPK COENY AIA THL ANZLY RYHTY SKLUY ANZFF GNE MEZ
New Zealand shares gained as the dollar sank following the official cash rate update, with Pushpay Holdings recovering from recent selling and SkyCity Entertainment Group continuing to gain.
KTHDY FBU FCREY NZR FRCEF FTRRF KMD SKC PPSHY FBU VTHPF GTK KMD
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET